Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression

Transplant Proc. 1993 Feb;25(1 Pt 2):1400-1.

Authors

V McAlister¹, D Grant, A Roy, Z Yilmaz, C Ghent, W Wall

Affiliation

¹ Department of Surgery, University of Western Ontario, London, Canada.

PMID: 8442154

No abstract available

MeSH terms

Adult
Antilymphocyte Serum / adverse effects
Antilymphocyte Serum / therapeutic use*
Cyclosporine / therapeutic use
Female
Follow-Up Studies
Graft Rejection
Humans
Incidence
Liver Transplantation / adverse effects
Liver Transplantation / immunology*
Lymphoproliferative Disorders / epidemiology
Lymphoproliferative Disorders / etiology*
Male
Muromonab-CD3 / adverse effects
Muromonab-CD3 / therapeutic use*
Prednisolone / therapeutic use
Retrospective Studies
Time Factors

Substances

Antilymphocyte Serum
Muromonab-CD3
Cyclosporine
Prednisolone